Vaccine Events & Conferences
This new international conference will be organized at the Tiara Park Atlantico Hotel in the Porto, Portugal (image courtesy of the World Factbook, CIA).
RSV Vaccines for the World (14-16 October 2013)
14 - 16 October 2013
Human respiratory syncytial virus (HRSV) is a major cause of upper and lower respiratory tract illness in infants and young children worldwide. Despite its importance as a respiratory pathogen, there is currently no licensed vaccine for prophylaxis of HRSV infection.
There are several hurdles complicating the development of a RSV vaccine: 1) incomplete immunity to natural RSV infection leading to frequent re-infection, 2) immature immune system and maternal antibodies of newborn infants who are the primary subject population, and 3) imbalanced Th2-biased immune responses to a past vaccine candidate led to exacerbated pulmonary disease. After the failure of an initial trial featuring formalin-inactivated virus as a RSV vaccine, more careful and deliberate efforts have been made towards the development of safe and effective RSV vaccines without vaccine-enhanced disease. Currently a wide array of RSV vaccine strategies is being developed, including live-attenuated viruses, protein subunit-based, and vector-based candidates. Though licensed vaccines remain to be developed, concerted efforts will lead researchers to reach the goal of attaining safe and effective RSV vaccines in the near future.
This new international conference will aim to bring together RSV researchers and other interested parties and researchers to hear updates on progress towards the successful implementation of vaccines/vaccine strategies against the RSV pathogen. RSVVW 2013 will be of interest to researchers/contributors from academic programmes, industrial, governmental and regulatory groups.
Find out more visit http://www.meetingsmanagement.co.uk/index.php?option=com_content&view=article&id=110&Itemid=226